Two new broker notes out last week on this one -

Collins Stewart gives a target valuation for the combined entity of 26 million or 156p per share

Edison Investments embedded valuation is 31m - Indicating a 100% gain in share price from current levels. They suggest that using the current embedded valuation model, the current value of Angles six non-exited ventures is only 5.5m - suggesting Angle to be SIGNIFICANTLY UNDERVALUED

Have a look

Up and away..

I'm kicking myself I passed on this one! I put NYO and FTE in my isa today--are you in those Mitzy?

Yep holding from 20p moneyplus could rocket to a couple of quid or go bust...will see.

Dear me its down 10%..

Are the wheels coming away now ?

Maybe Tara will have to start a Angle 500 a share thread to get it back up :-))

lol..

Where is Tara today..lol.

Guys this is going all the way.

Wow this is great up 23% and more.

down 15% lol.

Course it's going down, most of the profits were made from a profit on a PXS sale,
now to keep making those kind of profits they need to keep finding a stock that did what Pxs did which was 1p or less upto a 23p high, you need a crystal ball to do that every 6 months and would be lucky to that every six years, a huge pump and dump that has completely fizzled out and now the stock will only attract day traders trying to skim on the bounces intraday.

Part of an email I received today morning:

...Angle aims to secure a deal for its other major investment, 78%-owned Parsortix, by April 2011. Parsortix has developed the first ever non-invasive testing platform for the unborn baby. Pregnant women have a very small number of their baby's cells circulating in their blood; at most one foetal cell for 500 million maternal cells. Parsortix has developed a separation device, which can isolate intact foetal cells in maternal blood (as opposed to merely DNA fragments) when only 1.5ml of maternal blood is flowed through the device. The current method of testing carries substantial risk for both mother and baby, and is limited to high risk category patients where an invasive procedure can be justified.

Parsortix's method would be both cheaper and safer than conventional testing, so the market potential is pretty obvious. In the US market alone there are currently 375,000 such invasive tests undertaken per annum leaving the remaining 2.2 million pregnancies with no advance warning of potential problems. Assuming 11 million births per annum in industrialised countries and a cost of $200 per test, capturing just 3% of this market would generate substantial royalties (at 15%: c.$10 million per annum). News of a commercial partner for this technology on the lines of the Novocellus deal could drive the shares sharply higher in the near future. Buy. http://uk-analyst.com/shop/page-article/action-article.show/id-130003216

those in before today's hike should consider selling and buying back later!!! :-))))

WH Ireland note:
"ANGLE has announced that its 85% owned US-based portfolio company, Parsortix Inc. has completed a study demonstrating that its cell separation device reproducibly isolates and captures tumour cells in cancer patient blood, and emphasises that the cancer cells can be identified within the device without requiring a complicated cell extraction process. These are highly promising findings, which ANGLE believes give the technology an immediate market application in cancer research enabling sales of the product for research purposes from the second half of 2012.
Following this, the next step is to replicate these results in larger clinical trials to obtain US and European regulatory marketing approvals, which would enable Parsortix Inc. to sell the technology as a cost-effective, non-invasive, reliable screening tool to improve cancer treatment through early detection of cancer and monitoring of cancer patients while receiving treatment and those in remission. ANGLE estimates that the addressable clinical market for a simple circulating tumour cells counting device in the US alone exceeds $4 billion per annum."

one for the future here when sp reverses

gibby

re - those in before today's hike should consider selling and buying back later!!! :-))))


The time is not right for taking profits, I would say it has to go much much higher than the 56p at the time of you comment, think about a price close to 100p, though 85p could be a difficult price to go over

A lovely intraday UP trend, only falling a bit at 4pm after steady pause, as the profit takers (trades ) were busy cashing in for the day.

expect good comments on the press tomorrow and brokers making new updates

from ...growth company

ANGLE soars on cancer breakthrough
28/09/2011 Robert Tyerman

Shares in intellectual property backer ANGLE (AGL) have doubled on successful cancer cell separation by its US diagnostics company, Parsortix.

Guildford-based ANGLE says Parsortix, of which it owns 85 per cent, has 'validated' that its patented cell separation device can capture cancer cells added to blood.

AIM-quoted ANGLE says this device can be used, on a reproducible basis, to 'isolate and capture very small numbers of cancer cells from whole blood'. The company declares that the device 'appears to capture efficiently all of the cancer cells, avoiding the risk of failing to detect cancer cells in a blood sample' and 'allows the identification of cancer cells within the device, without requiring a complicated cell extraction process'.

ANGLE contends that the Parsortix device has immediate market application for research and says it has started talking to 'several of the world's leading cancer research institutes', with the aim of selling the product for research as early as the second half of next year. The company adds that it has also opened discussions about collaborating with major global diagnostic concerns.

Beyond this lies the possibility of selling a product direct, subject to key regulatory approvals, and targeting the blood test market, estimated to be worth more than 2.5 billion in the USA alone. ANGLE says its target is to seek approval from the US Food and Drug Administration and the European authorities by mid-2013, allowing commercial sales for cancer detection, cancer patient monitoring and post-treatment monitoring.

Andew Newland, founder, chief executive and substantial ANGLE shareholder, says Parsortix's cancer diagnostic 'offers an outstanding commercial opportunity'. Investors agree and have sent the shares, highlighted by Growth Company Investor in July at 27p, up 28.25p today to 56.25p, valuing the company at nearly 20 million.

Hold on for now.

ANGLE soars on cancer breakthrough

Proactive investors

In the meantime, todays big news from Angle (LON:AGL) went somewhat unnoticed, buried under the pile of reported from the oil and gas sector.

However, the company emerged among the most actively discussed stocks on message boards after seeing its share price double on the announcement that its 85 percent owned company Parsortix has validated that its cell separation device can capture cancer cells added to blood.

The group has already entered discussions with what it said were several of the world's leading cancer research institutes and reported strong interest in such a product, which would require regulatory approval for use for research purposes.

Angle is targeting to sell the product for research purposes as early as the second half of 2012.

We see this as not just a major validation of the Parsortix technology, but a significant broadening of Angles commercial opportunity...by this point, we would anticipate Parsortix to have attracted commercial interest from majors, said analysts at Collins Stewart.

The broker currently has a target price of 44 pence for the stock, however, it may want to update it after the companys share price rose from 28 pence to 56 pence this afternoon.

However, Collins Stewart noted in todays report that its valuation only presently ascribes partial value to 1 venture. The broker added that the success of any of the opportunities in its venture portfolio would highlight significant upside optionality in the Groups current share price.

Many investors following Angle agreed, noting that even after the increase, the company still has a market cap of 20 million, which, in their opinion, does not reflect the commercial potential of Parsortix.

http://www.proactiveinvestors.co.uk/companies/news/33689/wednesdays-most-followed-man-group-red-emperor-resources-dominos-pizza-angle-plc-33689.html

hi macho ref 77 / 81 - you will note i only said consider selling to buy back later, which means keep an eye on level 2 - be sensible as opposed to greedy and if happy cash in - i did not say sell but only consider